{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:52:35Z","timestamp":1794243155347,"version":"4.9.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.eprac.2025.12.003","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:41:11Z","timestamp":1765989671000},"page":"416-426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic Value of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis of Nodal Involvement, Distant Metastases, Recurrence, and Mortality"],"prefix":"10.1016","volume":"32","author":[{"given":"Elisa","family":"Gatta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Pirola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gandossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Maltese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Morandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Delbarba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Casella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4317-1232","authenticated-orcid":false,"given":"Carlo","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.eprac.2025.12.003_bib1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.003_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CCO.0000000000000022","article-title":"New insights in risk stratification of differentiated thyroid cancer","volume":"26","author":"Papaleontiou","year":"2014","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"10.1016\/j.eprac.2025.12.003_bib3","first-page":"1454","article-title":"High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma","volume":"63","author":"Kimura","year":"2003","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.eprac.2025.12.003_bib4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jnci\/95.8.625","article-title":"BRAF mutation in papillary thyroid carcinoma","volume":"95","author":"Cohen","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.003_bib5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1159\/000443032","article-title":"Meta-analyses of association between BRAF(V600E) mutation and clinicopathological features of papillary thyroid carcinoma","volume":"38","author":"Zhang","year":"2016","journal-title":"Cell Physiol Biochem"},{"issue":"12","key":"10.1016\/j.eprac.2025.12.003_bib6","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1210\/jc.2012-2104","article-title":"BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis","volume":"97","author":"Li","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2025.12.003_bib7","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/cncr.26500","article-title":"The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis","volume":"118","author":"Kim","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.eprac.2025.12.003_bib8","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"issue":"8","key":"10.1016\/j.eprac.2025.12.003_bib9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.eprac.2025.12.003_bib10","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1210\/jc.2003-030838","article-title":"BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2025.12.003_bib11","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2265.2005.02389.x","article-title":"The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma","volume":"63","author":"Kim","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.eprac.2025.12.003_bib12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2265.2005.02367.x","article-title":"No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan","volume":"63","author":"Liu","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.003_bib13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1677\/erc.1.01086","article-title":"Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature","volume":"13","author":"Fugazzola","year":"2006","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"10.1016\/j.eprac.2025.12.003_bib14","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1210\/jc.2006-2707","article-title":"BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism","volume":"92","author":"Durante","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.003_bib15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1677\/ERC-07-0212","article-title":"BRAF(V600E) mutation and the biology of papillary thyroid cancer","volume":"15","author":"Frasca","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"18","key":"10.1016\/j.eprac.2025.12.003_bib16","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.2008.20.1426","article-title":"BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer","volume":"27","author":"Xing","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.eprac.2025.12.003_bib17","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/modpathol.2010.116","article-title":"Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma","volume":"23","author":"Jung","year":"2010","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.eprac.2025.12.003_bib18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/BF03346593","article-title":"BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic","volume":"33","author":"Sykorova","year":"2010","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.003_bib19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.anl.2011.07.011","article-title":"BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma","volume":"39","author":"Ahn","year":"2012","journal-title":"Auris Nasus Larynx"},{"issue":"13","key":"10.1016\/j.eprac.2025.12.003_bib20","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1245\/s10434-011-1781-5","article-title":"Both BRAF V600E mutation and older age (\u2265 65 years) are associated with recurrent papillary thyroid cancer","volume":"18","author":"Howell","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.003_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1530\/EJE-12-0010","article-title":"Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer","volume":"167","author":"Lee","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.003_bib22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1349-7006.2011.02161.x","article-title":"Notch1 receptor as a marker of lymph node metastases in papillary thyroid cancer","volume":"103","author":"Park","year":"2012","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.eprac.2025.12.003_bib23","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1600-0463.2011.02844.x","article-title":"BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients","volume":"120","author":"Pelttari","year":"2012","journal-title":"Apmis"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.003_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/ERC-12-0309","article-title":"Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND","volume":"20","author":"Alzahrani","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.eprac.2025.12.003_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/1477-7819-11-291","article-title":"The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors","volume":"11","author":"Choi","year":"2013","journal-title":"World J Surg Oncol"},{"issue":"11","key":"10.1016\/j.eprac.2025.12.003_bib26","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1001\/jamaoto.2013.4501","article-title":"Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the university of California, San Francisco, experience","volume":"139","author":"Gouveia","year":"2013","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.eprac.2025.12.003_bib27","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/hed.22997","article-title":"BRAFV600E mutation in fine-needle aspiration aspirates: association with poorer prognostic factors in larger papillary thyroid carcinomas","volume":"35","author":"Lee","year":"2013","journal-title":"Head Neck"},{"issue":"9","key":"10.1016\/j.eprac.2025.12.003_bib28","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1210\/jc.2013-1584","article-title":"Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers","volume":"98","author":"Li","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2025.12.003_bib29","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1089\/thy.2013.0036","article-title":"Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center","volume":"23","author":"Lim","year":"2013","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2025.12.003_bib30","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/cen.12433","article-title":"BRAF mutation in follicular variant of papillary thyroid carcinoma is associated with unfavourable clinicopathological characteristics and malignant features on ultrasonography","volume":"81","author":"Chai","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.eprac.2025.12.003_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/07435800.2013.879169","article-title":"The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study","volume":"39","author":"Daliri","year":"2014","journal-title":"Endocr Res"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.003_bib32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3892\/ol.2013.1713","article-title":"Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma","volume":"7","author":"He","year":"2014","journal-title":"Oncol Lett"},{"issue":"4","key":"10.1016\/j.eprac.2025.12.003_bib33","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3803\/EnM.2014.29.4.505","article-title":"The frequency and clinical implications of the BRAF(V600E) mutation in papillary thyroid cancer patients in Korea over the past two decades","volume":"29","author":"Hong","year":"2014","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"4","key":"10.1016\/j.eprac.2025.12.003_bib34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.biopha.2014.03.008","article-title":"The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma","volume":"68","author":"Pelizzo","year":"2014","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"10.1016\/j.eprac.2025.12.003_bib35","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1089\/thy.2013.0675","article-title":"The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome","volume":"24","author":"Russo","year":"2014","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.003_bib36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s12020-013-0068-y","article-title":"Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer","volume":"46","author":"Shao","year":"2014","journal-title":"Endocrine"},{"issue":"25","key":"10.1016\/j.eprac.2025.12.003_bib37","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2025.12.003_bib38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1089\/thy.2012.0585","article-title":"Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAF V600E-prevalent papillary thyroid cancer population","volume":"24","author":"Yim","year":"2014","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2025.12.003_bib39","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10147-014-0754-7","article-title":"Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?","volume":"20","author":"Kwak","year":"2015","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.eprac.2025.12.003_bib40","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/his.12562","article-title":"Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V600E expression in thyroid cancer","volume":"66","author":"Wang","year":"2015","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.eprac.2025.12.003_bib41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00428-016-2027-5","article-title":"In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF (V600E) mutation","volume":"469","author":"Nasirden","year":"2016","journal-title":"Virchows Arch"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2025.12.003_bib42","first-page":"E1019","article-title":"Potential relationship between Hashimoto's thyroiditis and BRAF(V600E) mutation status in papillary thyroid cancer","volume":"38","author":"Zeng","year":"2016","journal-title":"Head Neck"},{"issue":"6","key":"10.1016\/j.eprac.2025.12.003_bib43","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/cen.13423","article-title":"Response to therapy of papillary thyroid cancer of known BRAF status","volume":"87","author":"Kowalska","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.003_bib44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","article-title":"Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality","volume":"3","author":"Liu","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eprac.2025.12.003_bib45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3389\/fendo.2019.00839","article-title":"Molecular predictors for advanced papillary thyroid carcinoma recurrence","volume":"10","author":"de Castro","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.eprac.2025.12.003_bib46","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.21037\/gs-20-244","article-title":"BRAF V600E mutation correlates with aggressive clinico-pathological features but does not influence tumor recurrence in papillary thyroid carcinoma-10-year single-center results","volume":"9","author":"Tabriz","year":"2020","journal-title":"Gland Surg"},{"issue":"4","key":"10.1016\/j.eprac.2025.12.003_bib47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bjorl.2020.07.007","article-title":"Characterization of BRAF mutation in patients older than 45 years with well-differentiated thyroid carcinoma","volume":"88","author":"Barreno","year":"2022","journal-title":"Braz J Otorhinolaryngol"},{"key":"10.1016\/j.eprac.2025.12.003_bib48","article-title":"Validation of dynamic risk stratification and impact of BRAF in risk assessment of thyroid cancer, a nation-wide multicenter study","volume":"13","author":"P\u00e9rez-Fern\u00e1ndez","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.eprac.2025.12.003_bib49","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6562149","article-title":"The prognostic implication of the BRAF V600E mutation in papillary thyroid cancer in a Chinese population","volume":"2022","author":"Ye","year":"2022","journal-title":"Int J Endocrinol"},{"issue":"16","key":"10.1016\/j.eprac.2025.12.003_bib50","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.3390\/cancers15164053","article-title":"Impact of BRAFV600E mutation on event-free survival in patients with papillary thyroid carcinoma: a retrospective study in a Romanian population","volume":"15","author":"Nechifor-Boil\u0103","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.003_bib51","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12020-023-03564-8","article-title":"BRAF (V600E) mutation in papillary thyroid microcarcinoma: is it a predictor for the prognosis of patients with intermediate to high recurrence risk?","volume":"84","author":"Cao","year":"2024","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.eprac.2025.12.003_bib52","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1245\/s10434-024-14935-4","article-title":"BRAF V600E mutation lacks association with poorer clinical prognosis in papillary thyroid carcinoma","volume":"31","author":"Lai","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.003_bib53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13044-024-00209-4","article-title":"Correlation between gene mutations and clinical characteristics in papillary thyroid cancer: a retrospective analysis of BRAF mutations and RET rearrangements","volume":"17","author":"Uno","year":"2024","journal-title":"Thyroid Res"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.003_bib54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12022-025-09859-y","article-title":"Prevalence and clinical impact of BRAF p.V600E mutation in papillary thyroid carcinoma","volume":"36","author":"Brumfield","year":"2025","journal-title":"Endocr Pathol"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.003_bib55","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s12020-025-04177-z","article-title":"Analysis of prognostic factors and establishment of a recurrence risk prediction model for papillary thyroid carcinoma based on BRAF stratification","volume":"88","author":"Hu","year":"2025","journal-title":"Endocrine"},{"issue":"24","key":"10.1016\/j.eprac.2025.12.003_bib56","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1001\/jama.2019.18528","article-title":"Changes in trends in thyroid cancer incidence in the United States, 1992 to 2016","volume":"322","author":"Powers","year":"2019","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.eprac.2025.12.003_bib57","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMp1604412","article-title":"Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis","volume":"375","author":"Vaccarella","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.12.003_bib58","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamaoto.2014.1","article-title":"Current thyroid cancer trends in the United States","volume":"140","author":"Davies","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"18","key":"10.1016\/j.eprac.2025.12.003_bib59","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","article-title":"Increasing incidence of thyroid cancer in the United States, 1973-2002","volume":"295","author":"Davies","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.eprac.2025.12.003_bib60","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0002-9343(94)90321-2","article-title":"Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer","volume":"97","author":"Mazzaferri","year":"1994","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.12.003_bib61","first-page":"751","article-title":"Updated American joint committee on cancer\/Tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth edition)","volume":"27","author":"Tuttle","year":"2017","journal-title":"What Changed and Why? Thyroid"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.003_bib62","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ecl.2014.02.010","article-title":"Update on differentiated thyroid cancer staging","volume":"43","author":"Momesso","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"12","key":"10.1016\/j.eprac.2025.12.003_bib63","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1210\/jc.2005-0987","article-title":"BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer","volume":"90","author":"Xing","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.003_bib64","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/cncr.22754","article-title":"Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis","volume":"110","author":"Lee","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.eprac.2025.12.003_bib65","doi-asserted-by":"crossref","first-page":"E754","DOI":"10.1210\/jc.2013-3734","article-title":"TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas","volume":"99","author":"Melo","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.12.003_bib66","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1530\/ERC-13-0210","article-title":"Highly prevalent TERT promoter mutations in aggressive thyroid cancers","volume":"20","author":"Liu","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"10.1016\/j.eprac.2025.12.003_bib67","doi-asserted-by":"crossref","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","article-title":"Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","volume":"98","author":"Landa","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2025.12.003_bib68","doi-asserted-by":"crossref","first-page":"E1130","DOI":"10.1210\/jc.2013-4048","article-title":"TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer","volume":"99","author":"Liu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6892","key":"10.1016\/j.eprac.2025.12.003_bib69","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.eprac.2025.12.003_bib70","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3390\/cancers12113146","article-title":"Genetic landscape of papillary thyroid carcinoma and nuclear architecture: an overview comparing pediatric and adult populations","volume":"12","author":"Rangel-Pozzo","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.eprac.2025.12.003_bib71","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3390\/cancers13071625","article-title":"Site-specific metastasis and survival in papillary thyroid cancer: the importance of brain and multi-organ disease","volume":"13","author":"Toraih","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25013230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25013230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:14:01Z","timestamp":1781525641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25013230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1530891X25013230"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.12.003","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Value of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis of Nodal Involvement, Distant Metastases, Recurrence, and Mortality","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}